Company to review and discuss the results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913.

Dr. Sarah Barenbaum is an Assistant Professor of Clinical Medicine at Weill Cornell Medical College and an Assistant Attending Physician at NewYork-Presbyterian Hospital. Dr. Barenbaum specializes in the care of patients with obesity and weight-related medical complications. Dr. Barenbaum sees patients at the Comprehensive Weight Control Center, and also with the GI Metabolic and Bariatric Surgery program, where she serves as the Obesity Medicine Director. Dr. Barenbaum received her B.A. from Yale University. She received her M.D. from Drexel University College of Medicine. Dr. Barenbaum completed both her Residency & Obesity Medicine Fellowship at Weill Cornell Medicine/NewYork-Presbyterian Hospital.

Dr. Daniel Lee is a Board-certified Psychiatrist with 14+ years of experience spanning clinical psychiatry, clinical pharmacology, medical monitoring, regulatory affairs, and CNS drug development. He has an extensive background in both clinical and industry settings, including direct patient care, psychiatric assessments, and medical oversight in academic, military, FDA, and pharmaceutical environments. With over a decade of leadership in CNS drug development Dr Lee has supported Phase I-IV trials, suicidality assessments, psychiatric drug safety monitoring, and clinical pharmacology studies. He has deep expertise in trial design, medical monitoring, FDA regulatory reviews, and industry-spnsored research, collaborating with small biotech and large pharmaceutical companies to advance psychiatric and neurological therapeutics as a well respected and insightful consultant.